biostudies-literatureUnknown11(1)Gutweniger SThis trial evaluates whether nocturnal oxygen therapy (NOT) during a stay at 2048 m improves altitude-induced exercise intolerance in lowlanders with chronic obstructive pulmonary disease (COPD). 32 lowlanders with moderate to severe COPD, mean ± SD forced expiratory volume in the first second of expiration (FEV₁) 54 ± 13% predicted, stayed for 2 days at 2048 m twice, once with NOT, once with placebo according to a randomized, crossover trial with a 2-week washout period at < 800 m in-between. Semi-supine, constant-load cycle exercise to exhaustion at 60% of maximal work-rate was performed at 490 m and after the first night at 2048 m. Endurance time was the primary outcome. Additional outcomes were cerebral tissue oxygenation (CTO), arterial blood gases and breath-by-breath measurements ( http://www.ClinicalTrials.gov NCT02150590). Mean ± SE endurance time at 490 m was 602 ± 65 s, at 2048 m after placebo 345 ± 62 s and at 2048 m after NOT 293 ± 60 s, respectively (P < 0.001 vs. 490 m). Mean difference (95%CI) NOT versus placebo was - 52 s (- 174 to 70), P = 0.401. End-exercise pulse oximetry (SpO₂), CTO and minute ventilation ([Formula: see text]) at 490 m were: SpO₂ 92 ± 1%, CTO 65 ± 1%, [Formula: see text] 37.7 ± 2.0 L/min; at 2048 m with placebo: SpO₂ 85 ± 1%, CTO 61 ± 1%, [Formula: see text] 40.6 ± 2.0 L/min and with NOT: SpO₂ 84 ± 1%; CTO 61 ± 1%; [Formula: see text] 40.6 ± 2.0 L/min (P < 0.05, SpO₂, CTO at 2048 m with placebo vs. 490 m; P = NS, NOT vs. placebo). Altitude-related hypoxemia and cerebral hypoxia impaired exercise endurance in patients with moderate to severe COPD and were not prevented by NOT.Scientific reports20355https://www.ebi.ac.uk/biostudies/studies/S-EPMC8514448biostudies-literatureEffect of nocturnal oxygen therapy on exercise performance of COPD patients at 2048 m: data from a randomized clinical trial.PMC8514448Scheiwiller PMAeschbacher SSHuber FGutweniger SUlrich SLatshang TDFurian MFlueck DBloch KEHasler EDLichtblau MfalseEffect of nocturnal oxygen therapy on exercise performance of COPD patients at 2048 m: data from a randomized clinical trial.This trial evaluates whether nocturnal oxygen therapy (NOT) during a stay at 2048 m improves altitude-induced exercise intolerance in lowlanders with chronic obstructive pulmonary disease (COPD). 32 lowlanders with moderate to severe COPD, mean ± SD forced expiratory volume in the first second of expiration (FEV₁) 54 ± 13% predicted, stayed for 2 days at 2048 m twice, once with NOT, once with placebo according to a randomized, crossover trial with a 2-week washout period at < 800 m in-between. Semi-supine, constant-load cycle exercise to exhaustion at 60% of maximal work-rate was performed at 490 m and after the first night at 2048 m. Endurance time was the primary outcome. Additional outcomes were cerebral tissue oxygenation (CTO), arterial blood gases and breath-by-breath measurements ( http://www.ClinicalTrials.gov NCT02150590). Mean ± SE endurance time at 490 m was 602 ± 65 s, at 2048 m after placebo 345 ± 62 s and at 2048 m after NOT 293 ± 60 s, respectively (P < 0.001 vs. 490 m). Mean difference (95%CI) NOT versus placebo was - 52 s (- 174 to 70), P = 0.401. End-exercise pulse oximetry (SpO₂), CTO and minute ventilation ([Formula: see text]) at 490 m were: SpO₂ 92 ± 1%, CTO 65 ± 1%, [Formula: see text] 37.7 ± 2.0 L/min; at 2048 m with placebo: SpO₂ 85 ± 1%, CTO 61 ± 1%, [Formula: see text] 40.6 ± 2.0 L/min and with NOT: SpO₂ 84 ± 1%; CTO 61 ± 1%; [Formula: see text] 40.6 ± 2.0 L/min (P < 0.05, SpO₂, CTO at 2048 m with placebo vs. 490 m; P = NS, NOT vs. placebo). Altitude-related hypoxemia and cerebral hypoxia impaired exercise endurance in patients with moderate to severe COPD and were not prevented by NOT.2021-01-01T00:00:00Z2021 Oct2024-10-18T03:02:44.546Z2022-02-11T12:13:48.346ZS-EPMC85144483464584210.1038/s41598-021-98395-w